GC Therapeutics, a Cambridge, MA-based biopharmaceutical company advancing cell therapy-based medicines, raised $65M in Series A funding.
The round was led by Cormorant Asset Management with participation from Mubadala Capital, Andreessen Horowitz (a16z) Bio + Health, Medical Excellence Capital, Cercano Management and Pear VC, bringing total capital raised to $75M.
GC Therapeutics is a biopharmaceutical company created to scale and improve cell therapy-based medicines. Its induced pluripotent stem cell (iPSC) programming platform, TFome™ (tee-eff-ome), integrates advancements in synthetic biology, gene editing, cell engineering and machine learning to overcome the therapeutic development and scaling complexities associated with cell therapy and improve patient access across a broad range of disease areas.
The company intends to use the funds to expand operations and its development efforts. Its initial focus is on developing and cell therapies for gastrointestinal, neurological and immunological diseases.
GCTx co-founders include:
- Parastoo Khoshakhlagh, Ph.D., chief executive officer
- Alex Ng, Ph.D., chief scientific officer
- Cory Smith, Ph.D., scientific co-founder and head of discovery platforms
- George Church, Ph.D., professor of genetics at Harvard Medical School and core faculty member and synthetic biology lead at the Wyss Institute
GCTx board of directors and advisers include:
- Ray Kelleher, M.D., Ph.D., managing director, Cormorant Asset Management
- Vineeta Agarwala, M.D., Ph.D., general partner, a16z Bio + Health
- Alaa Halawa, MBA, executive director and head of U.S. ventures, Mubadala Capital
- John Maraganore, Ph.D., CEO and principal, JMM Innovations, LLC, founding CEO, Alnylam Pharmaceuticals, Inc.
- Steve Paul, M.D., former CEO, Karuna Therapeutics, former EVP, Eli Lilly and Company, co-founder and board chair, Rapport Therapeutics and Seaport Therapeutics
FinSMEs
23/09/2024